Understanding how some pancreatic cancer patients respond well to treatments
Official title: The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer
Funded at Sloan-Kettering Inst Can Research · NIH-10908413 · Data updated 2026-11-12
This study is looking at how certain genes and molecules affect how well patients with advanced pancreatic cancer respond to different treatments, with the hope of finding ways to improve care and survival for everyone facing this tough disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 20, 2022 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $2,281,895 |
| NIH project number | 5P50CA257881-03 |
| Project ID | NIH-10908413 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with locally advanced or metastatic pancreatic ductal adenocarcinoma.
✕Less likely to help
Patients with early-stage pancreatic cancer or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates the genetic and molecular factors that contribute to exceptional responses to therapies in patients with pancreatic ductal adenocarcinoma (PDAC). By analyzing both standard and immune-based treatments, the project aims to identify mechanisms of resistance and sensitivity to these therapies. The goal is to use this knowledge to guide clinical management and improve survival rates for all patients with pancreatic cancer. The research will focus on advanced stages of the disease, where treatment options are most critical.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment strategies for pancreatic cancer, potentially improving survival rates.
How similar studies have gone: Previous research has shown promising results in understanding treatment responses in pancreatic cancer, indicating potential for success in this approach.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: O'reilly, Eileen Mary — Sloan-Kettering Inst Can Research
- Study coordinator: O'reilly, Eileen Mary
Related research
Other NIH-funded projects on the same topics.
-
SPORE in Pancreas Cancer at MSK: advancing personalized therapy for pancreatic cancer
A large, multi-year program at Memorial Sloan Kettering aims to tailor pancreatic cancer treatment to each patient’s biology to improve survival and outcomes.
-
How nerves influence pancreatic cancer progression and immune response
This NIH grant tests whether nerves and nerve signals affect pancreatic cancer growth and the body’s immune response, with findings that could lead to new therapies for people with pancreatic cancer.
-
Overcoming barriers in pancreatic cancer therapy
A cancer research project that explores how pancreatic tumors resist treatment and how to improve therapies by studying tumor cells and their surrounding environment in animal models.
-
How low oxygen makes pancreatic cancer cells more aggressive
This project looks at whether low oxygen areas inside pancreatic tumors cause cancer cells to become more aggressive and resist chemotherapy, aiming to help people with pancreatic cancer.
-
How different dietary fats affect pancreatic cancer start and growth
This project looks at whether specific kinds of high-fat diets speed up or slow the start and growth of pancreatic cancer to help people at risk understand dietary effects.
-
Immune signals that make pancreatic cancer more stem‑like and aggressive
Looking at whether an immune signal called IL‑22, working through its receptor IL‑22RA1 and STAT3, makes pancreatic ductal adenocarcinoma cells more stem‑like and aggressive to guide future treatments for people with PDAC.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.